{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:10:43Z","timestamp":1792012243963,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s11914-009-0003-6","type":"journal-article","created":{"date-parts":[[2009,3,7]],"date-time":"2009-03-07T00:25:06Z","timestamp":1236385506000},"page":"12-17","source":"Crossref","is-referenced-by-count":18,"title":["Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment"],"prefix":"10.1007","volume":"7","author":[{"given":"Piet","family":"Geusens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,8]]},"reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11914-003-0010-y","volume":"1","author":"P.P. Geusens","year":"2003","unstructured":"Geusens PP: Review of guidelines for testing and treatment of osteoporosis. Curr Osteoporos Rep 2003, 1:59\u201365.","journal-title":"Curr Osteoporos Rep"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ncprheum0773","volume":"4","author":"P.P. Geusens","year":"2008","unstructured":"Geusens PP, Roux CH, Reid DM, et al.: Drug insight: choosing a drug treatment strategy for women with osteoporosis: an evidence-based clinical perspective. Nat Clin Pract Rheumatol 2008, 4:240\u2013248.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"3_CR3","unstructured":"Papapoulos S, Compston I: Debate: Excessive suppression of bone remodeling by antiresorptive agents\u2014fact or fiction? 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16\u201320, 2007."},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1138\/20050144","volume":"2","author":"I.R. Reid","year":"2005","unstructured":"Reid IR: Long-term use of alendronate. BoneKEy-Osteovision 2005, 2:10\u201312.","journal-title":"BoneKEy-Osteovision"},{"key":"3_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","volume":"74","author":"K. Briot","year":"2007","unstructured":"Briot K, Tr\u00e9molli\u00e8res F, Thomas T, et al.: How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007, 74:24\u201331.","journal-title":"Joint Bone Spine"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncpendmet0618","volume":"3","author":"M.E. Kraenzlin","year":"2007","unstructured":"Kraenzlin ME, Meier C: Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women? Nat Clin Pract Endocrinol Metab 2007, 3:686\u2013687.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"3_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1138\/20050145","volume":"2","author":"S.E. Papapoulos","year":"2005","unstructured":"Papapoulos SE: Long-term therapy of osteoporosis with bisphosphonates: evidence and implications for daily practice BoneKEy-Osteovision 2005, 2:13\u201319.","journal-title":"BoneKEy-Osteovision"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jbspin.2007.09.003","volume":"74","author":"R. Rizzoli","year":"2007","unstructured":"Rizzoli R: Long-term strategy in the management of postmenopausal osteoporosis. Joint Bone Spine 2007, 74:540\u2013543.","journal-title":"Joint Bone Spine"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"R.G. Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733\u2013759.","journal-title":"Osteoporos Int"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","volume":"89","author":"M.R. McClung","year":"2004","unstructured":"McClung MR, Wasnich RD, Hosking DJ, et al.: Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 2004, 89:4879\u20134885.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6Pt1","key":"3_CR11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","volume":"11","author":"R.D. Wasnich","year":"2004","unstructured":"Wasnich RD, Bagger YZ, Hosking DJ, et al.: Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004, 11(6 Pt 1):622\u2013630.","journal-title":"Menopause"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"H.G. Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer J-P, et al.: Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189\u20131199.","journal-title":"N Engl J Med"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"D.M. Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, et al.: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927\u20132938.","journal-title":"JAMA"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"D.D. Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, et al.: Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462\u2013468.","journal-title":"Calcif Tissue Int"},{"key":"3_CR15","unstructured":"Schwartz AV, Bauer DC, Cauley A, et al.: Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX trial [abstract 1057]. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16\u201320 2007."},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"N.B. Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski P, et al.: Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19:365\u2013372.","journal-title":"Osteoporos Int"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1138\/20060248","volume":"4","author":"M.R. Allen","year":"2007","unstructured":"Allen MR, Burr B: Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy-Osteovision 2007, 4:49\u201360.","journal-title":"BoneKEy-Osteovision"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","volume":"22","author":"R.D. Chapurlat","year":"2007","unstructured":"Chapurlat RD, Arlot M, Burt-Pichat B, et al.: Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007 22:1502\u20131509.","journal-title":"J Bone Miner Res"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","volume":"41","author":"J.J. Stepan","year":"2007","unstructured":"Stepan JJ, Burr DB, Pavo I, et al.: Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007, 41:378\u2013385.","journal-title":"Bone"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1138\/20070271","volume":"4","author":"M.M. McDonald","year":"2007","unstructured":"McDonald MM, Schindeler A, Little DG: Bisphosphonate treatment and fracture repair. BoneKEy-Osteovision 2007, 4:236\u2013251.","journal-title":"BoneKEy-Osteovision"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"K.W. Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, et al.: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799\u20131809.","journal-title":"N Engl J Med"},{"key":"3_CR22","doi-asserted-by":"crossref","unstructured":"Solomon DH, Hochberg MC, Mogun H, et al.: The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 2008 Oct 9 (Epub ahead of print).","DOI":"10.1007\/s00198-008-0759-z"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T. Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65:415\u2013423.","journal-title":"J Oral Maxillofac Surg"},{"key":"3_CR24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1359\/jbmr.060712","volume":"21","author":"E. Shane","year":"2006","unstructured":"Shane E, Goldring S, Christakos S, et al.: Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006, 21:1503\u20131505.","journal-title":"J Bone Miner Res"},{"key":"3_CR25","first-page":"1391","volume":"35","author":"A.A. Khan","year":"2008","unstructured":"Khan AA, S\u00e1ndor GK, Dore E, et al.: Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008, 35:1391\u20131397.","journal-title":"J Rheumatol"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00005373-199707000-00027","volume":"43","author":"S. Salminen","year":"1997","unstructured":"Salminen S, Pihlajam\u00e4ki H, Avikainen V, et al.: Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997, 43:117\u2013122.","journal-title":"J Trauma"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"C.V. Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294\u20131301.","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S. Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B, et al.: Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852\u2013860.","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"P.D. Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R, et al.: Early responsiveness of women with osteoporosis to teriparatide following therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93:3785\u20133793.","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jocd.2007.04.002","volume":"10","author":"A.J. Laster","year":"2007","unstructured":"Laster AJ, Lewiecki EM, ISCD Board of Directors: Vertebral fracture assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A white paper of the International Society for Clinical Densitometry. J Clin Densitom 2007, 10:227\u2013238.","journal-title":"J Clin Densitom"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"J.A. Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, et al.: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385\u2013397.","journal-title":"Osteoporos Int"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"E.S. Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013\u20131022.","journal-title":"Mayo Clin Proc"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"A.M. Gallagher","year":"2008","unstructured":"Gallagher AM, Rietbrock S, Olson M, van Staa TP: Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008, 23:1569\u20131575.","journal-title":"J Bone Miner Res"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-009-0003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-009-0003-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-009-0003-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:33:44Z","timestamp":1559435624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-009-0003-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11914-009-0003-6","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}